替妥木单抗与甲状腺眼病不断演变中的治疗格局
本文通过PubMed检索1979至2021年文献,综述甲状腺眼病(TED)的靶向治疗进展。替妥木单抗作为胰岛素样生长因子1受体(IGF-1R)抑制性单克隆抗体,随机临床试验证实其疗效并获美国食品药品监督管理局批准,正在美国逐渐取代免疫抑制剂成为活动性中重度TED的一线治疗。TED管理正转向靶向治疗与多学科协作时代,仍需临床指南和更多研究进一步指导与优化治疗。
要点
- 替妥木单抗是IGF-1R抑制性单克隆抗体,随机临床试验证实其对TED有效并获美国食品药品监督管理局批准。
- 替妥木单抗正在美国逐渐取代免疫抑制剂,成为活动性中重度TED的一线治疗。
- TED管理转向靶向治疗与多学科协作,仍需临床指南和更多研究进一步指导与优化治疗。
核心结论
- TED管理正转向靶向治疗与多学科协作的时代。
- 替妥木单抗显示出优于传统治疗的疗效,并改变了治疗与手术方案。
- 仍需临床指南和更多研究来进一步指导和优化治疗。
研究设计与样本
- 本文为文献综述,检索PubMed中1979年至2021年期间发表的文献。
- 检索词包括甲状腺眼病、替妥木单抗、靶向治疗、Graves病、Graves眼病、甲状腺功能障碍性视神经病变及相关术语的不同组合。
主要发现
- 随机临床试验证实替妥木单抗对TED有效,促成美国食品药品监督管理局批准。
- 替妥木单抗正在美国逐渐取代免疫抑制剂,成为活动性中重度TED的一线治疗。
- 新出现的报告也显示替妥木单抗用于疾病其他阶段。
- 近期数据强调了不良事件的风险因素和筛查方案,以最大化患者安全。
- 通过内分泌科医生与眼科医生有效合作制定的个体化治疗方案,旨在提高TED治疗的安全性和结局。
临床怎么用
- 替妥木单抗正在美国逐渐取代免疫抑制剂,成为活动性中重度TED的一线治疗。
- 通过内分泌科医生与眼科医生有效合作制定个体化治疗方案,以提高TED治疗的安全性和结局。
- 近期数据强调了不良事件的风险因素和筛查方案,以最大化患者安全。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid eye disease (TED) is a sight-threatening and debilitating autoimmune condition, with limited therapies available, that often poses diagnostic and therapeutic challenges. In recent years, the treatment landscape has shifted to early intervention with targeted therapy. METHODS: A PubMed review of the literature was conducted for the period between 1979 and 2021. Search terms included thyroid eye disease, teprotumumab, targeted therapy, Graves disease, Graves ophthalmopathy, dysthyroid optic neuropathy, and related terms in different combinations. Novel biologic therapies for TED have emerged as alternatives to traditional steroid regimens in recent years. New insights into TED pathophysiology have uncovered the role of the insulin-like growth factor 1 receptor (IGF-1R) and led to the development of teprotumumab, an IGF-1R-inhibiting monoclonal antibody. RESULTS: Randomized clinical trials demonstrating the efficacy of teprotumumab for TED led to Food and Drug Administration approval. Teprotumumab is gradually replacing immunosuppressive agents as first-line therapy in the United States for active moderate-to-severe TED, while emerging reports also show its use in other stages of the disease. Recent data highlight risk factors for adverse events and screening protocols to maximize patient safety. Personalized therapeutic plans developed through effective partnership between endocrinologists and ophthalmologists aim to enhance the safety and outcomes of TED treatments and improve care for this complex disease. CONCLUSION: TED management is shifting to an era of targeted therapy with multidisciplinary care. Teprotumumab has demonstrated superior efficacy to conventional treatments and has transformed our therapeutic and surgical algorithms. Clinical guidelines and additional studies are needed to further guide and refine therapy.
引用
- Kossler AL, Douglas R, Dosiou C, et al. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease. J Clin Endocrinol Metab. 2022. PMID: 36346685. doi:10.1210/clinem/dgac168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。